Elevation Oncology, Inc. (ELEV)

Market Cap	34.29M
Revenue (ttm)	n/a
Net Income (ttm)	-41.95M
Shares Out	59.12M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,474,497
Open	0.620
Previous Close	0.626
Day's Range	0.561 - 0.660
52-Week Range	0.440 - 5.830
Beta	1.25
Analysts	Strong Buy
Price Target	7.20 (+1,141.38%)
Earnings Date	Nov 6, 2024

About ELEV

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company’s lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: ELEV
• Website: https://elevationoncology.com

Analyst Forecast

According to 5 analysts, the average rating for ELEV stock is "Strong Buy." The 12-month stock price forecast is $7.2, which is an increase of 1,141.38% from the latest price.

Price Target

$7.2

(1,141.38% upside)

Analyst Consensus: Strong Buy